Apotex Suffers Defeat In Acular Dispute

Law360, New York (September 11, 2007, 12:00 AM EDT) -- In a major setback for Apotex Inc., a federal judge has found that the Canadian drug maker’s application for a generic version of anti-inflammatory eye treatment Acular infringed a patent held by Roche Palo Alto LLC and licensed to Allergan LLC.

Judge Martin J. Jenkins of the U.S. District Court for the Northern District of California on Tuesday granted summary judgment in favor of plaintiffs Roche and Allergan, finding that Apotex’s abbreviated new drug application (ANDA) violated the Acular patent, and that the patent was valid...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.